IL-17和IL-17受体抑制剂在广泛性脓疱性银屑病治疗中的作用。

K. Plachouri, V. Chourdakis, S. Georgiou
{"title":"IL-17和IL-17受体抑制剂在广泛性脓疱性银屑病治疗中的作用。","authors":"K. Plachouri, V. Chourdakis, S. Georgiou","doi":"10.1358/dot.2019.55.9.3020159","DOIUrl":null,"url":null,"abstract":"Generalized pustular psoriasis (GPP) is a severe psoriasis form that can be refractory to several systemic treatments. The role of interleukin (IL)-17/ T-helper 17 (Th17) axis inhibitors in the therapy of GPP is not fully established. The objective of this paper is to summarize the existing information on the efficacy and safety of secukinumab, ixekizumab and brodalumab in GPP. Articles published in the English language and derived from the databases MEDLINE (PubMed), Embase and Scopus were assessed for this study. Although the existing data on the potential therapeutic benefit of these agents in the treatment of GPP are encouraging, further studies are needed so as to provide sufficient evidence for their use in this serious condition.","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"55 9 1","pages":"587-593"},"PeriodicalIF":0.0000,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":"{\"title\":\"The role of IL-17 and IL-17 receptor inhibitors in the management of generalized pustular psoriasis.\",\"authors\":\"K. Plachouri, V. Chourdakis, S. Georgiou\",\"doi\":\"10.1358/dot.2019.55.9.3020159\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Generalized pustular psoriasis (GPP) is a severe psoriasis form that can be refractory to several systemic treatments. The role of interleukin (IL)-17/ T-helper 17 (Th17) axis inhibitors in the therapy of GPP is not fully established. The objective of this paper is to summarize the existing information on the efficacy and safety of secukinumab, ixekizumab and brodalumab in GPP. Articles published in the English language and derived from the databases MEDLINE (PubMed), Embase and Scopus were assessed for this study. Although the existing data on the potential therapeutic benefit of these agents in the treatment of GPP are encouraging, further studies are needed so as to provide sufficient evidence for their use in this serious condition.\",\"PeriodicalId\":85144,\"journal\":{\"name\":\"Medicamentos de actualidad. Drugs of today\",\"volume\":\"55 9 1\",\"pages\":\"587-593\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicamentos de actualidad. Drugs of today\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1358/dot.2019.55.9.3020159\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicamentos de actualidad. Drugs of today","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1358/dot.2019.55.9.3020159","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 8

摘要

泛发性脓疱性银屑病(GPP)是一种严重的银屑病,对几种全身治疗都是难治的。白细胞介素(IL)-17/T-helper 17(Th17)轴抑制剂在GPP治疗中的作用尚未完全确定。本文的目的是总结关于secukinumab、ixekizumab和brodalumab在GPP中的疗效和安全性的现有信息。本研究评估了以英语发表的文章,这些文章来源于MEDLINE(PubMed)、Embase和Scopus数据库。尽管关于这些药物在治疗GPP中的潜在治疗益处的现有数据令人鼓舞,但还需要进一步的研究,以便为它们在这种严重疾病中的使用提供足够的证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The role of IL-17 and IL-17 receptor inhibitors in the management of generalized pustular psoriasis.
Generalized pustular psoriasis (GPP) is a severe psoriasis form that can be refractory to several systemic treatments. The role of interleukin (IL)-17/ T-helper 17 (Th17) axis inhibitors in the therapy of GPP is not fully established. The objective of this paper is to summarize the existing information on the efficacy and safety of secukinumab, ixekizumab and brodalumab in GPP. Articles published in the English language and derived from the databases MEDLINE (PubMed), Embase and Scopus were assessed for this study. Although the existing data on the potential therapeutic benefit of these agents in the treatment of GPP are encouraging, further studies are needed so as to provide sufficient evidence for their use in this serious condition.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
New product intros [ezetimibe/pitavastatin (new combination), ozoralizumab, ripasudil/brimonidine (new combination), spesolimab, valemetostat tosylate (first-in-class), valoctocogene roxaparvovec] Asparaginase Erwinia chrysanthemi for acute lymphoblastic leukemia and lymphoblastic lymphoma. Bimekizumab for psoriasis. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma. Pamiparib for germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1